PDCD1 and neoplasm: For example, lenvatinib has demonstrated immunomodulatory activity via CD8+ T cells populations and improved antitumor activity when combined with anti-PD-1 therapy [65], and cabozantinib induces tumor cell changes increasing sensitivity to T cell-mediated lysis [66].